vTv Therapeutics (VTVT) Current Deferred Revenue (2015 - 2026)

vTv Therapeutics (VTVT) has 12 years of Current Deferred Revenue data on file, last reported at $500000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $500000.0; the trailing twelve-month figure through Mar 2026 stood at $500000.0 (changed N/A YoY), and the FY2025 full-year result was $18.7 million, changed N/A from the prior year.
• Current Deferred Revenue fell to $500000.0 in Q1 2026, from $18.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $18.7 million in Q4 2025 to a low of $17000.0 in Q4 2022.
• A 5-year average of $7.2 million and a median of $35000.0 in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 71769.23% in 2023 and slumped 99.91% in 2024, its largest moves.
• Tracing VTVT's Current Deferred Revenue over 5 years: stood at $17000.0 in 2022, then changed by 0.0% to $17000.0 in 2023, then changed by 0.0% to $17000.0 in 2024, then jumped by 109900.0% to $18.7 million in 2025, then sank by 97.33% to $500000.0 in 2026.
• Business Quant data shows VTVT's Current Deferred Revenue at $500000.0 in Q1 2026, $18.7 million in Q4 2025, and $17000.0 in Q3 2024.